TAM receptors are pleiotropic inhibitors of the innate immune response

被引:833
作者
Rothlin, Carla V. [1 ]
Ghosh, Sourav [2 ]
Zuniga, Elina I. [3 ]
Oldstone, Michael B. A. [3 ]
Lemke, Greg [1 ]
机构
[1] Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA
[2] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA
[3] Scripps Res Inst, Mol & Integrat Neurosci Lab, La Jolla, CA 92037 USA
关键词
D O I
10.1016/j.cell.2007.10.034
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The activation of Toll-like receptors (TLRs) in dendritic cells (DCs) triggers a rapid inflammatory response to pathogens. However, this response must be tightly regulated because unrestrained TLR signaling generates a chronic inflammatory milieu that often leads to autoimmunity. We have found that the TAM receptor tyrosine kinases-Tyro3, Axl, and Mer- broadly inhibit both TLR and TLR-induced cytokine-receptor cascades. Remarkably, TAM inhibition of inflammation is transduced through an essential stimulator of inflammation - the type I interferon receptor (IFNAR) - and its associated transcription factor STAT1. TLR induction of IFNAR-STAT1 signaling upregulates the TAM system, which in turn usurps the IFNAR-STAT1 cassette to induce the cytokine and TLR suppressors SOCS1 and SOCS3. These results illuminate a self-regulating cycle of inflammation, in which the obligatory, cytokine-dependent activation of TAM signaling hijacks a proinflammatory pathway to provide an intrinsic feedback inhibitor of both TLR- and cytokine-driven immune responses.
引用
收藏
页码:1124 / 1136
页数:13
相关论文
共 43 条
[1]  
Akira S, 2006, CURR TOP MICROBIOL, V311, P1
[2]   Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[3]   Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis [J].
Angelillo-Scherrer, A ;
de Frutos, PG ;
Aparicio, C ;
Melis, E ;
Savi, P ;
Lupu, F ;
Arnout, J ;
Dewerchin, M ;
Hoylaerts, MF ;
Herbert, M ;
Collen, D ;
Dahlbäck, B ;
Carmeliet, P .
NATURE MEDICINE, 2001, 7 (02) :215-221
[4]   Type I interferon in systemic lupus erythematosus and other autoimmune diseases [J].
Banchereau, Jacques ;
Pascual, Virginia .
IMMUNITY, 2006, 25 (03) :383-392
[5]   Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large [J].
Beutler, Bruce ;
Jiang, Zhengfan ;
Georgel, Philippe ;
Crozat, Karine ;
Croker, Ben ;
Rutschmann, Sophie ;
Du, Xin ;
Hoebe, Kasper .
ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :353-389
[6]   Elevated growth-arrest-specific protein 6 plasma levels in patients with severe sepsis [J].
Borgel, D ;
Clauser, S ;
Bornstain, C ;
Bièche, I ;
Bissery, A ;
Remones, V ;
Fagon, JY ;
Aiach, M ;
Diehl, JL .
CRITICAL CARE MEDICINE, 2006, 34 (01) :219-222
[7]   Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological "Damage Limitation" Effect and an Important Potential Opportunity for Therapy [J].
Broad, Andrea ;
Jones, David E. J. ;
Kirby, John A. .
CURRENT MEDICINAL CHEMISTRY, 2006, 13 (21) :2487-2502
[8]   The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus [J].
Brouwer, JLR ;
Bijl, M ;
Veeger, NJGM ;
Kluin-Nelemans, HC ;
van der Meer, J .
BLOOD, 2004, 104 (01) :143-148
[9]   RETRACTED: A promiscuous liaison between IL-15 receptor and Axl receptor tyrosine kinase in cell death control (Retracted Article. See vol 30, pg 627, 2011) [J].
Budagian, V ;
Bulanova, E ;
Orinska, Z ;
Thon, L ;
Mamat, U ;
Bellosta, P ;
Basilico, C ;
Adam, D ;
Paus, R ;
Bulfone-Paus, S .
EMBO JOURNAL, 2005, 24 (24) :4260-4270
[10]  
Camenisch TD, 1999, J IMMUNOL, V162, P3498